Association between dietary patterns and obesity-related metabolic phenotypes in Chinese middle-aged and older adults: a cross-sectional study
October 6, 2025 / Obesity prevention / Metabolic health / Dietary patterns / Elderly nutrition / Chinese population
In a study of over 15,000 Chinese adults, diets rich in eggs, dairy, and plant-based foods were linked to lower rates of obesity-related metabolic disorders, while high grain and meat intake increased metabolically unhealthy obesity risk.
Metabolic Bariatric Surgery Outperforms GLP-1s in Weight Loss With Lower Long-Term Costs
October 2, 2025 / Bariatric surgery / GLP-1 treatment / Obesity management / Weight loss outcomes / Healthcare costs
Metabolic bariatric surgery delivers significantly greater weight loss and lower long-term costs than GLP-1 therapies for class 1 and 3 obesity, prompting reconsideration of its role as a last-line treatment in obesity management.
Elderberry juice boosts key genes for metabolic flexibility in overweight adults
October 3, 2025 / Elderberry juice / Metabolic flexibility / Gene expression / Anthocyanins health / Overweight adults
Elderberry juice enhanced gene expression linked to metabolic flexibility in overweight adults, showing significantly more transcriptional activity than placebo during fasting-to-fed transitions—highlighting its potential role in improving metabolic health via anthocyanin-driven pathways.
Use of weight loss drugs before bariatric surgery has soared in recent years, study finds
October 3, 2025 / GLP-1 medications / Bariatric surgery trends / Obesity treatment / Type 2 diabetes / Weight loss drugs
Use of GLP-1 weight loss drugs before bariatric surgery has surged 16-fold since 2020, reflecting a major shift toward combined pharmacologic and surgical obesity treatment strategies across patients with and without type 2 diabetes.
Surprising study reveals what really kills fatty liver disease patients
October 4, 2024 / MASLD mortality / Cardiometabolic risk / Fatty liver disease / Hypertension impact / HDL cholesterol
In MASLD patients, high blood pressure, diabetes, and low HDL cholesterol significantly increase mortality risk—especially hypertension, which exceeds diabetes in predictive power—highlighting the urgent need for targeted cardiometabolic management regardless of demographic factors.
New Study Reveals Metabolically Active Visceral Fat Drives Aggressiveness in Endometrial Cancer
October 4, 2025 / Visceral fat / Endometrial cancer / Tumor aggressiveness / PET/CT imaging / Metabolic activity
Visceral fat with high metabolic activity—measured via PET/CT—is strongly linked to increased aggressiveness and lymph node involvement in endometrial cancer, highlighting a key biologic factor beyond obesity in tumor progression.
Translating cellular senescence research into clinical practice for metabolic disease
October 6, 2025 / Cellular senescence / Metabolic disease / Senotherapeutics / Obesity treatment / Aging research
Targeting cellular senescence offers promising therapeutic potential for metabolic diseases by disrupting the cycle of stress-induced dysfunction linked to obesity and aging, though translation to clinical practice requires validated biomarkers and well-designed trials.
Heart diseases caused by fatty liver: Understanding the link between metabolic dysfunction and cardiovascular health
October 7, 2025 / Fatty liver disease / Cardiovascular risk / MASLD impact / Liver-heart connection / Metabolic dysfunction
Medically Focused Summary (≤40 words):
Fatty liver disease, particularly MASLD, significantly increases cardiovascular risk through mechanisms like inflammation, insulin resistance, and lipid imbalance—highlighting the need for early intervention to protect both liver and heart health.
Study finds weight-loss surgery better than meds for long-term health
October 4, 2025 / Fatty liver disease / Cardiovascular risk / MASLD impact / Liver-heart connection / Metabolic dysfunction
Fatty liver disease, particularly MASLD, significantly increases cardiovascular risk through mechanisms like inflammation, insulin resistance, and lipid imbalance—highlighting the need for early intervention to protect both liver and heart health.
QMI obesity management course Cycle II launched
October 6, 2024 / Obesity management / Bariatric care / Healthcare training / Qatar health strategy / Multidisciplinary approach
Qatar Metabolic Institute launched Cycle II of its obesity management program to strengthen multidisciplinary care, improve access, and align with Qatar’s National Health Strategy by training healthcare professionals in evidence-based, patient-centered obesity and bariatric care.
Metabolic-Associated Steatohepatitis (MASH) Treatment: Medication, Lifestyle Changes, and More
October 2, 2025 / MASH treatment / Liver fibrosis / Resmetirom benefits / Semaglutide MASH / Fatty liver therapy
MASH, a progressive liver disease marked by fat buildup and inflammation, can be managed through lifestyle changes and two approved medications—resmetirom and semaglutide—which target liver fibrosis, fat metabolism, and related metabolic conditions like obesity and diabetes.
Sterile inflammation in MASH: emerging role of extracellular RNA and therapeutic strategies
October 6, 2025 / MASH inflammation / Extracellular RNA / DAMP signaling / Liver fibrosis / RNase1 therapy
Sterile inflammation, driven by extracellular RNA and DAMP pathways like TLR3 and cGAS–STING, plays a central role in MASH progression. Targeting eRNA-induced immune signaling with RNase1 offers a promising new therapeutic strategy for liver inflammation and fibrosis.
Sagimet Biosciences Initiates Phase 1 Trial for Combination Therapy Targeting Metabolic Dysfunction-Associated Steatohepatitis
October 1, 2025 / MASH treatment / Denifanstat resmetirom / Liver fibrosis therapy / Phase 1 trial / Combination therapy
Sagimet Biosciences has launched a Phase 1 trial evaluating a combination of denifanstat and resmetirom for MASH, aiming to assess safety, pharmacokinetics, and potential for a once-daily therapy targeting liver fibrosis in advanced disease.
Researchers develop fat-like nanoparticles to treat fatty liver disease
October 3 23, 2025 / MASH therapy / RNA nanomedicine / Fatty liver treatment / Lipid nanoparticles / SPTLC2 targeting
NUS researchers developed lipid nanoparticle RNA therapy targeting the SPTLC2 gene, reducing liver fat, inflammation, and fibrosis in MASH. This precision approach may offer a safer, more effective alternative to current limited treatments for fatty liver disease.
Metabolic syndrome increases the risk of suicide attempt: evidence from a population-based cohort and genomic analysis
October 6, 2025 / Metabolic syndrome / Suicide risk / UK Biobank study / Genetic correlation / Suicide prevention
A UK Biobank study found metabolic syndrome significantly increases suicide attempt risk, even in low-risk groups, with supporting genetic evidence. Addressing MetS may offer a novel strategy for suicide prevention and improved risk assessment.
Study finds surge in the use of weight loss drugs among bariatric surgery patients
October 3, 2025 / GLP-1 medications / Bariatric surgery trends / Obesity treatment / Type 2 diabetes / Weight loss drugs
GLP-1 use among bariatric surgery patients surged sixteenfold from 2020 to 2024, with notable increases in both diabetic and non-diabetic populations, highlighting a shift toward integrated pharmacologic and surgical strategies in obesity and Type 2 diabetes care.
The global cardiovascular–liver–metabolic syndemic: epidemiology, trends and challenges
October 6, 2025 / CLM syndemic / Metabolic disease trends / Liver-cardiometabolic health / Precision prevention / Health equity strategies
Cardiovascular, liver, and metabolic diseases form a global syndemic with shared biological and socioeconomic drivers. A unified micro–meso–macro framework is needed to enable precision prevention, improve health equity, and address rising disease burdens collectively.
Ultra-processed foods destroy health in 3 ‘alarming’ ways: ‘We were shocked’
October 6, 2025 / Ultra-processed foods / Men’s health risks / Metabolic disease / Cardiovascular impact / Cognitive decline
New research from the University of Copenhagen identifies three alarming pathways through which ultra-processed foods harm men’s health—beyond calories and nutrients—linking them to increased risk of metabolic, cardiovascular, and cognitive diseases, regardless of overall nutrient intake.
Indonesia’s Unpad Students Develop Real-Time Metabolic Syndrome Monitoring Smartband
October 5, 2025 / Metabolic syndrome / Smart health device / Real-time monitoring / NIRS technology / IoT healthcare
Unpad students developed MetaBand, a real-time smartband using Near-Infrared Spectroscopy (NIRS) to monitor key metabolic syndrome indicators—cholesterol, glucose, and blood pressure—integrated with an app for early detection and health tracking via IoT-based technology.